NCT03079219View on ClinicalTrials.gov

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
Breast Cancer
Interventions
DRUG

Experimental drug: Aprepitant

Day 1: 125mg QD; Day 2 to Day 3: 80mg QD

DRUG

Experimental drug: Ondansetron

Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose

DRUG

Experimental drug: Dexamethasone

Day 1: 12mg QD

DRUG

Experimental drug: Olanzapine

Day 1 to Day 5: 10mg QD

DRUG

Standard: Aprepitant

Day 1: 125mg QD, Day 2 to Day3: 80mg QD

DRUG

Standard: Ondansetron

Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose

DRUG

Standard: Dexamethasone

Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

CCTU

OTHER

NCT03079219 - Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients | Biotech Hunter | Biotech Hunter